logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

VHIO develops a precision immunotherapy for breast cancer

Source: redaccionmedica.com

Researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona have achieved that immunotherapy attacks only the tumor cells of a type of breast cancer in patients who do not respond to other treatments, an action “at home” that solves one of The main challenges for this novel strategy in Oncology.

The study, published in Science Translational Medicine, has demonstrated the efficacy of a drug (p95HER2-TCB) that is responsible for guiding lymphocytes to the tumor cell through a protein that is only present in tumor cells (p95HER2 ), has explained in a statement the VHIO.

A magnet for the tumor

The leader of the work, who is director of the Preclinical Research Program of this center, Joaquín Arribas, explained that the drug works like a “magnet” that causes the immune system of the patient to be attracted to the tumor cells and attack them , without this response affecting the rest of healthy cells.

“The problem of treatment with immunotherapy is that lymphocytes, in addition to targeting tumor cells, also attack healthy tissues”, so this finding avoids the side effect and makes lymphocytes go directly to the tumor cells in which This protein is present, said the first author of the study, Irene Rius.

Arribas added: “This creates a kind of very specific bridge between the patient’s lymphocyte and its tumor cell that allows us a very targeted and controlled response for HER2 + breast tumors.”

Resistance to therapies

Advanced and metastatic cancers generally develop resistance to therapies, making the tumor resistant and spreading, and the immune system is particularly suited to fight disseminated disease, provided it is adequately equipped to recognize malignant cells.

Patients with breast cancer tumors in which the HER2 + protein is present, which they estimate to be approximately 10 percent of the total and 40 percent of the HER2 + tumors, may benefit: “Although apparently there are not many patients in the beginning that can benefit, the certain thing is that those that do it could obtain an enormous benefit “, has emphasized the researcher.

“Very specific” therapies

The finding of this research, which has completed its preclinical phase after ten years of study since this protein was discovered, follows the philosophy of the most personalized therapies, “to offer very specific therapies to groups of patients who do not benefit from other treatments. ”

“Although 70 percent of patients with breast cancer HER2 + are healing, there is a 30 percent who do not and now may have an option”, has put in value Arribas, also professor ICREA and scientific director of Ciberonc .

The scientist has led a team with scientists from Ciberonc and several research groups of VHIO, both from its Preclinical and Translational Program and from the Clinical Program, and the Oncology and Pathology Departments of Vall d’Hebron Hospital, in a collaborative effort.

In Distefar we want to congratulate these researchers for this great new strategy in Oncology

Related entries

19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más
14 September, 2023

Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros


Leer más
12 September, 2023

Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry


Leer más

Recent Posts

  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry
  • The rise of combination therapies in cancer opens up an opportunity for patients, but requires improved access procedures
  • The 22nd Meeting of the Spanish Pharmaceutical Industry will focus on the reform of European legislation and its impact on Spain

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.